Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

东方财富证券股份有限公司研究员何玮2021年4月29日发布研报《智飞生物(300122)2020年报点 评：自研代理双轮驱动 自研产品进入收获期》称，维持智飞生物"增持"评级。 (责任编辑：徐自立) 中国经济网北京1月28日讯 智飞生物(300122.SZ)今日股价下跌，截至收盘报17.86元，跌幅 4.18%。 2021年5月17日，智飞生物股价创下历史最高点231.19元。 ...

证券代码：300122 证券简称：智飞生物 公告编号：2026-06 重庆智飞生物制品股份有限公司（以下简称"公司"）全资子公司安徽智飞 龙科马生物制药有限公司（以下简称"智飞龙科马"）于近日收到国家药品监督 管理局核准签发的《药品注册申请终止通知书》，同意智飞龙科马撤回儿童型四 价流感病毒裂解疫苗和流感病毒裂解疫苗的注册申请。现将相关情况公告如下： 一、药品基本情况 药品名称：四价流感病毒裂解疫苗（6 月龄-35 月龄人群）、流感病毒裂解 疫苗（6 月龄-35 月龄人群） 注册分类：预防用生物制品 3.3 类 受理号：CXSS2400106、CXSS2400118 通知书编号：2026L00065、2026L00064 重庆智飞生物制品股份有限公司 关于撤回药品注册申请的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 好。鉴于流感病毒的变异性特征及儿童群体免疫系统的特殊性，为更全面科学地 评价疫苗临床使用效果，结合公司研发策略与市场对高品质儿童疫苗的需求，经 审慎评估，公司决定撤回上述药品注册申请。公司将稳步推进补充研究，持续完 善临床证据链，继续推进 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [3] Core Insights - The recent policy released by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical retail sector is anticipated to see improved performance expectations due to favorable policies, with a recommendation to focus on quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin [6][33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Year-to-date, the pharmaceutical and biotechnology index has increased by 6.66%, outperforming the CSI 300 index by 5.1 percentage points, ranking 16th [11] - The best-performing sub-sector this week was pharmaceutical commerce, which rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] Stock Performance - Among 478 pharmaceutical and biotechnology stocks, 338 stocks increased, representing 70.71% of the total [22] - The top five A-share stocks by performance this week were: *ST Changyao (+70.37%), Hualan Biological Engineering (+32.21%), Kangzhong Medical (+25.47%), Hanshang Group (+20.06%), and Wanze Shares (+19.04%) [22] - In the Hong Kong market, 116 pharmaceutical and biotechnology stocks saw 32 stocks rise, accounting for 27.59% [25] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and optimize industry structure [28] - The FDA granted fast-track designation to CM336, a dual antibody developed by Kangnuo, for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia [31] Recommendations - The report suggests focusing on quality pharmacy enterprises in light of the favorable policies for the pharmaceutical retail sector [33] - It also highlights the potential for vaccine companies in response to the recent Nipah virus cases in India, recommending attention to companies like Zhifei Biological, Kangtai Biological, Watson Bio, and CanSino [34]

Market Overview - The A-share market exhibited a fluctuating and differentiated pattern last week, with major indices showing mixed performance and active rotation among hot sectors [1][7] - Institutions generally hold an optimistic outlook, believing the market is likely to trend upward [1][7] - As of January 25, over 950 companies have disclosed their 2025 earnings forecasts, with around 40% of these companies showing positive performance [1][7] Semiconductor Industry - The semiconductor industry, particularly companies related to artificial intelligence, data center construction, and domestic substitution, is expected to see strong earnings growth in 2025 [1][8] - Notable companies include: - Zhongwei Semiconductor expects revenue of approximately 1.122 billion yuan, a year-on-year increase of about 23%, and a net profit of 284 million yuan, up approximately 107% [8] - Juchip Technology anticipates revenue of 922 million yuan, a 41.44% increase, and a net profit of 204 million yuan, up 91.40% [2] - Baiwei Storage forecasts revenue between 10 billion to 12 billion yuan, a growth of 49.36% to 79.23%, and a net profit of 850 million to 1 billion yuan, a staggering increase of 427.19% to 520.22% [3][9] Pharmaceutical Industry - The pharmaceutical sector is experiencing a "polarized" performance, with over 60 companies disclosing earnings forecasts, about half of which are positive [1][9] - Key performers include: - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan, a year-on-year increase of 214% to 371% [10] - Shanghai Yizhong anticipates a net profit of 6 million to 7 million yuan, a growth of 760.18% to 903.54% [10] - However, companies like Zhifei Biological are projected to incur significant losses, with an expected net loss of 10.7 billion to 13.7 billion yuan [10][5] Banking Sector - As of January 25, eight listed banks have released earnings reports, with all showing year-on-year growth in net profit [5][11] - Key statistics include: - China Merchants Bank's total assets surpassing 13 trillion yuan, and Industrial Bank exceeding 11 trillion yuan [11] - The highest net profit growth among these banks is from Hangzhou Bank at 12.05%, followed by Shanghai Pudong Development Bank at 10.52% [11] - The growth drivers for banks include improved cost of liabilities and rapid growth in intermediary business income, with Ningbo Bank's net income from fees and commissions increasing by 30.72% [12]

Group 1 - The core viewpoint of the news highlights a recent pullback in the biopharmaceutical sector, with the Huatai-PineBridge Biopharmaceutical ETF (159839) declining by 2.08% while maintaining high trading volume, with nearly 600 million yuan in transactions for the day [1][4] - The ETF has seen continuous inflows, with a net subscription of over 54 million shares today and a total of over 73 million yuan in the last 10 days [1] - The ETF tracks the Guozheng Biopharmaceutical Index, which includes sectors such as CXO, vaccines, chemical drugs, blood products, and medical aesthetics, with the vaccine sector currently accounting for 15.1% of the index [6] Group 2 - A significant research breakthrough was reported by the Wuhan Institute of Virology, confirming that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this high-mortality emerging infectious disease [3] - The biopharmaceutical ETF's major component stocks mostly experienced declines, with Watson Bio and Zhi Fei Bio dropping over 6%, while Sanofi Biopharma saw an increase of over 10% [4][5] - The latest performance forecast from Sanofi Biopharma indicates an expected net profit of approximately 2.9 billion yuan for 2025, representing a year-on-year growth of 311.35% [4] Group 3 - Data from Guoxin Securities indicates a decrease in pharmaceutical holdings among funds, with the overall pharmaceutical holding ratio at 7.97%, down by 1.71 percentage points from the previous quarter [7] - The largest sub-sector in pharmaceutical holdings is chemical preparations and other biological products, while the internet pharmacy and other biological products saw the most significant decline in holdings [9] - The JPM 2026 conference highlighted the acceleration of internationalization among Chinese pharmaceutical companies, with significant technological breakthroughs in areas such as ADC and GLP-1, leading to increased global competitiveness [10][11]

Core Viewpoint - The recent Nipah virus outbreak in India has led to increased attention and investment in the A-share pharmaceutical sector, with significant capital inflows into medical ETFs despite some declines in stock prices [1][3]. Group 1: Market Activity - The medical ETF (159929) experienced a drop of over 1% today, following a previous day of gains, but attracted 64 million yuan in capital [1]. - Over the past 10 days, the ETF has seen net inflows for 9 days, accumulating nearly 300 million yuan [1]. - Trading activity remains robust, with intraday trading volume exceeding 120 million yuan [1]. Group 2: Nipah Virus Research - The Nipah virus outbreak in West Bengal, India, has resulted in deaths and the isolation of close contacts [3]. - A significant research study published in the journal Emerging Microbes & Infections confirms that the oral nucleoside drug VV116 shows promising antiviral activity against the Nipah virus, providing new hope for treatment and prevention [3]. Group 3: Company Updates - Sanofi's (三生国健) 2025 annual performance forecast indicates a net profit of approximately 2.9 billion yuan, reflecting a year-on-year increase of 311.35%, driven by a collaboration with Pfizer [4]. - Junshi Biosciences (君实生物) has completed the issuance of its first phase of technology innovation bonds for 2026, totaling 1 billion yuan, aimed at supporting drug research and development [4]. Group 4: Sector Trends - The pharmaceutical industry is expected to benefit from a favorable investment environment and policy support, particularly for innovative drugs and technologies [6][8]. - The medical manufacturing sector has shown a slight increase in industrial value added, while revenue and profit have seen minor declines [7]. - The healthcare expenditure in China has shown a year-on-year growth of 4.7% for the first 11 months of 2025, marking a recovery after two years of decline [7]. Group 5: Investment Strategies - Investment strategies for 2026 focus on innovation, international expansion, and marginal improvements in the pharmaceutical sector [8][9]. - Key areas of interest include innovative drugs, medical devices, and the integration of new technologies such as AI and brain-machine interfaces [8][9].

Group 1 - The recent outbreak of Nipah virus in West Bengal, India, has led to 5 confirmed cases, with one patient in critical condition, prompting enhanced preventive measures in neighboring countries like Thailand and Nepal [1] - Nearly 100 individuals have been placed under home quarantine, and infected patients are receiving treatment in hospitals in Kolkata and surrounding areas [1] - The Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infections and potentially fatal encephalitis, and there is currently no approved vaccine or specific treatment available [1][4] Group 2 - The stock prices of vaccine and in vitro diagnostic (IVD) sectors surged following the news, with companies like Hualan Biological (301207) and Jindike experiencing significant gains, reaching their daily limit [1][2] - The vaccine index rose by 6.60%, with notable increases in stock prices for companies such as Hualan Vaccine (20.00%), Jindike (19.98%), and Zhifei Biological (14.87%) [2] - The market response indicates a heightened interest in companies involved in vaccine development and diagnostic testing related to the Nipah virus [1][8] Group 3 - Nipah virus is classified as a high-pathogenicity pathogen with a mortality rate ranging from 40% to 75%, and it has been recognized as a significant public health threat for over 25 years [3][5] - The virus's natural reservoir is fruit bats, which can transmit the virus through contaminated food or environments, and outbreaks have primarily occurred in South and Southeast Asia [3][5] - Current detection methods include antibody and nucleic acid testing, with companies like Zhijiang Biological and Daan Gene developing specific test kits for Nipah virus detection [6][7] Group 4 - Companies are actively developing testing solutions, with Zhijiang Biological's Nipah virus PCR test kit achieving high sensitivity and rapid results, and Daan Gene's kit also showing promising detection capabilities [7] - Research into vaccines for Nipah virus is ongoing, with some candidates entering clinical trials, and monoclonal antibodies showing potential in compassionate use [8] - The stock prices of companies involved in vaccine development, such as Watson Bio, Zhifei Bio, and Hualan Vaccine, have seen increases, reflecting investor optimism regarding potential solutions to the Nipah virus threat [8]

Core Viewpoint - The recent outbreak of Nipah virus in West Bengal, India, has raised concerns, leading to increased preventive measures in neighboring countries and a significant rise in stock prices of vaccine and IVD companies in the A-share market [1][12]. Group 1: Nipah Virus Overview - Nipah virus (NiV) is a zoonotic RNA virus with a high mortality rate, classified as a biosafety level 4 pathogen by WHO, with a fatality rate ranging from 40% to 75% [6][8]. - The natural reservoir for Nipah virus is fruit bats, which can transmit the virus to humans through contaminated food or environments [6][8]. - Recent data indicates that India has experienced a resurgence of Nipah virus cases, particularly in Kerala and now West Bengal, with localized outbreaks showing high fatality rates [7][8]. Group 2: Market Impact - Following the news of Nipah virus cases, the A-share vaccine and IVD sectors saw a collective surge, with companies like Hualan Biological and Jindike hitting the daily limit up [1][12]. - Specific stock performances included Hualan Biological at 23.34 with a 20% increase, Jindike at 25.28 with a 19.98% increase, and others like Zhifei Biological and CanSino also showing significant gains [2][3]. Group 3: Detection and Response - Early detection of Nipah virus is crucial, with the incubation period ranging from 3 to 14 days, and initial symptoms resembling flu, which can lead to misdiagnosis [10][12]. - Various detection methods are in use, including antibody and nucleic acid tests, with companies like Zhijiang Biological and Daan Gene developing specific test kits for Nipah virus [10][11]. - The new revised "Law on Frontier Health and Quarantine" in China includes Nipah virus in its detection protocols, highlighting the importance of monitoring and response [10]. Group 4: Vaccine Development - Although there is currently no approved treatment for Nipah virus, research is ongoing, with vaccines entering clinical trials and monoclonal antibodies showing potential in compassionate use [12]. - Companies involved in vaccine development, such as Watson Bio, Zhifei Biological, and Hualan Biological, have seen stock price increases, reflecting investor optimism regarding potential future products [12].

Group 1: Nipah Virus Outbreak in India - The Nipah virus infection cases have been reported in West Bengal, India, with 5 confirmed cases, including healthcare workers, and nearly 100 individuals under home quarantine [1] - One patient is in critical condition, and the infected individuals are receiving treatment in Kolkata and surrounding hospitals [1] Group 2: Market Reaction - Following the news, the A-share market saw significant movements in sectors such as flu vaccines, diagnostic reagents, and chemical pharmaceuticals, with several stocks hitting the daily limit [2] - Notable stock performances include Hualan Vaccine (20% increase), Jindike (19.98% increase), and Zhifei Biological (14.87% increase) [2][3] Group 3: Vaccine and Diagnostic Kit Development - Companies in the IVD medical device sector, including Maike Biological and Cap Biological, launched Nipah virus test kits, with prices ranging from 100 to 2899 yuan [5][6] - The development of Nipah virus vaccines is considered technically feasible, but companies face challenges due to low vaccination willingness and market conditions [5] Group 4: Regulatory and Preventive Measures - China has strengthened its legal framework for controlling infectious diseases, including the Nipah virus, with new regulations effective from January 1, 2025 [7] - Enhanced health monitoring measures have been implemented at airports in Thailand for travelers from India due to the outbreak [7]